Global Drugs for Neuromyelitis Optica Market Growth 2020-2025
COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.
According to this latest study, the 2020 growth of Drugs for Neuromyelitis Optica will have significant change from previous year. By the most conservative estimates of global Drugs for Neuromyelitis Optica market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Drugs for Neuromyelitis Optica market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Neuromyelitis Optica market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Drugs for Neuromyelitis Optica, covering the supply chain analysis, impact assessment to the Drugs for Neuromyelitis Optica market size growth rate in several scenarios, and the measures to be undertaken by Drugs for Neuromyelitis Optica companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Glucocorticoids
Immunotherapies
Other
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Acute Attack
Remission Prophylactic Treatment
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Pfizer
CSL
Fresenius
Sandoz
Intas
Teva
Tianjin Kingyork
Gyjtrs
Baxter
NANG KUANG
Grifols
CBOP
Octapharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Drugs for Neuromyelitis Optica consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Drugs for Neuromyelitis Optica market by identifying its various subsegments.
Focuses on the key global Drugs for Neuromyelitis Optica manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Drugs for Neuromyelitis Optica with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Drugs for Neuromyelitis Optica submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Drugs for Neuromyelitis Optica?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Drugs for Neuromyelitis Optica Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for Neuromyelitis Optica Consumption 2015-2025
2.1.2 Drugs for Neuromyelitis Optica Consumption CAGR by Region
2.2 Drugs for Neuromyelitis Optica Segment by Type
2.2.1 Glucocorticoids
2.2.2 Immunotherapies
2.2.3 Other
2.3 Drugs for Neuromyelitis Optica Consumption by Type
2.3.1 Global Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
2.3.2 Global Drugs for Neuromyelitis Optica Revenue and Market Share by Type (2015-2020)
2.3.3 Global Drugs for Neuromyelitis Optica Sale Price by Type (2015-2020)
2.4 Drugs for Neuromyelitis Optica Segment by Application
2.4.1 Acute Attack
2.4.2 Remission Prophylactic Treatment
2.5 Drugs for Neuromyelitis Optica Consumption by Application
2.5.1 Global Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
2.5.2 Global Drugs for Neuromyelitis Optica Value and Market Share by Type (2015-2020)
2.5.3 Global Drugs for Neuromyelitis Optica Sale Price by Type (2015-2020)
3 Global Drugs for Neuromyelitis Optica by Company
3.1 Global Drugs for Neuromyelitis Optica Sales Market Share by Company
3.1.1 Global Drugs for Neuromyelitis Optica Sales by Company (2018-2020)
3.1.2 Global Drugs for Neuromyelitis Optica Sales Market Share by Company (2018-2020)
3.2 Global Drugs for Neuromyelitis Optica Revenue Market Share by Company
3.2.1 Global Drugs for Neuromyelitis Optica Revenue by Company (2018-2020)
3.2.2 Global Drugs for Neuromyelitis Optica Revenue Market Share by Company (2018-2020)
3.3 Global Drugs for Neuromyelitis Optica Sale Price by Company
3.4 Global Drugs for Neuromyelitis Optica Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Drugs for Neuromyelitis Optica Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Drugs for Neuromyelitis Optica Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Drugs for Neuromyelitis Optica by Regions
4.1 Drugs for Neuromyelitis Optica by Regions
4.2 Americas Drugs for Neuromyelitis Optica Consumption Growth
4.3 APAC Drugs for Neuromyelitis Optica Consumption Growth
4.4 Europe Drugs for Neuromyelitis Optica Consumption Growth
4.5 Middle East & Africa Drugs for Neuromyelitis Optica Consumption Growth
5 Americas
5.1 Americas Drugs for Neuromyelitis Optica Consumption by Countries
5.1.1 Americas Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020)
5.1.2 Americas Drugs for Neuromyelitis Optica Value by Countries (2015-2020)
5.2 Americas Drugs for Neuromyelitis Optica Consumption by Type
5.3 Americas Drugs for Neuromyelitis Optica Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Drugs for Neuromyelitis Optica Consumption by Regions
6.1.1 APAC Drugs for Neuromyelitis Optica Consumption by Regions (2015-2020)
6.1.2 APAC Drugs for Neuromyelitis Optica Value by Regions (2015-2020)
6.2 APAC Drugs for Neuromyelitis Optica Consumption by Type
6.3 APAC Drugs for Neuromyelitis Optica Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Drugs for Neuromyelitis Optica by Countries
7.1.1 Europe Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020)
7.1.2 Europe Drugs for Neuromyelitis Optica Value by Countries (2015-2020)
7.2 Europe Drugs for Neuromyelitis Optica Consumption by Type
7.3 Europe Drugs for Neuromyelitis Optica Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Drugs for Neuromyelitis Optica by Countries
8.1.1 Middle East & Africa Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Drugs for Neuromyelitis Optica Value by Countries (2015-2020)
8.2 Middle East & Africa Drugs for Neuromyelitis Optica Consumption by Type
8.3 Middle East & Africa Drugs for Neuromyelitis Optica Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Drugs for Neuromyelitis Optica Distributors
10.3 Drugs for Neuromyelitis Optica Customer
11 Global Drugs for Neuromyelitis Optica Market Forecast
11.1 Global Drugs for Neuromyelitis Optica Consumption Forecast (2021-2025)
11.2 Global Drugs for Neuromyelitis Optica Forecast by Regions
11.2.1 Global Drugs for Neuromyelitis Optica Forecast by Regions (2021-2025)
11.2.2 Global Drugs for Neuromyelitis Optica Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Drugs for Neuromyelitis Optica Forecast by Type
11.8 Global Drugs for Neuromyelitis Optica Forecast by Application
12 Key Players Analysis
12.1 Pfizer
12.1.1 Company Information
12.1.2 Drugs for Neuromyelitis Optica Product Offered
12.1.3 Pfizer Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Pfizer Latest Developments
12.2 CSL
12.2.1 Company Information
12.2.2 Drugs for Neuromyelitis Optica Product Offered
12.2.3 CSL Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 CSL Latest Developments
12.3 Fresenius
12.3.1 Company Information
12.3.2 Drugs for Neuromyelitis Optica Product Offered
12.3.3 Fresenius Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Fresenius Latest Developments
12.4 Sandoz
12.4.1 Company Information
12.4.2 Drugs for Neuromyelitis Optica Product Offered
12.4.3 Sandoz Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Sandoz Latest Developments
12.5 Intas
12.5.1 Company Information
12.5.2 Drugs for Neuromyelitis Optica Product Offered
12.5.3 Intas Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Intas Latest Developments
12.6 Teva
12.6.1 Company Information
12.6.2 Drugs for Neuromyelitis Optica Product Offered
12.6.3 Teva Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Teva Latest Developments
12.7 Tianjin Kingyork
12.7.1 Company Information
12.7.2 Drugs for Neuromyelitis Optica Product Offered
12.7.3 Tianjin Kingyork Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Tianjin Kingyork Latest Developments
12.8 Gyjtrs
12.8.1 Company Information
12.8.2 Drugs for Neuromyelitis Optica Product Offered
12.8.3 Gyjtrs Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Gyjtrs Latest Developments
12.9 Baxter
12.9.1 Company Information
12.9.2 Drugs for Neuromyelitis Optica Product Offered
12.9.3 Baxter Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Baxter Latest Developments
12.10 NANG KUANG
12.10.1 Company Information
12.10.2 Drugs for Neuromyelitis Optica Product Offered
12.10.3 NANG KUANG Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 NANG KUANG Latest Developments
12.11 Grifols
12.11.1 Company Information
12.11.2 Drugs for Neuromyelitis Optica Product Offered
12.11.3 Grifols Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Grifols Latest Developments
12.12 CBOP
12.12.1 Company Information
12.12.2 Drugs for Neuromyelitis Optica Product Offered
12.12.3 CBOP Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 CBOP Latest Developments
12.13 Octapharma
12.13.1 Company Information
12.13.2 Drugs for Neuromyelitis Optica Product Offered
12.13.3 Octapharma Drugs for Neuromyelitis Optica Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Octapharma Latest Developments
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Drugs for Neuromyelitis Optica Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Drugs for Neuromyelitis Optica Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Drugs for Neuromyelitis Optica Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Glucocorticoids
Table 7. Major Players of Immunotherapies
Table 8. Major Players of Other
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
Table 11. Global Drugs for Neuromyelitis Optica Revenue by Type (2015-2020) ($ million)
Table 12. Global Drugs for Neuromyelitis Optica Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Drugs for Neuromyelitis Optica Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Drugs for Neuromyelitis Optica Consumption Market Share by Application (2015-2020)
Table 16. Global Drugs for Neuromyelitis Optica Value by Application (2015-2020)
Table 17. Global Drugs for Neuromyelitis Optica Value Market Share by Application (2015-2020)
Table 18. Global Drugs for Neuromyelitis Optica Sale Price by Application (2015-2020)
Table 19. Global Drugs for Neuromyelitis Optica Sales by Company (2017-2019) (K Units)
Table 20. Global Drugs for Neuromyelitis Optica Sales Market Share by Company (2017-2019)
Table 21. Global Drugs for Neuromyelitis Optica Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Drugs for Neuromyelitis Optica Revenue Market Share by Company (2017-2019)
Table 23. Global Drugs for Neuromyelitis Optica Sale Price by Company (2017-2019)
Table 24. Global Drugs for Neuromyelitis Optica Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Drugs for Neuromyelitis Optica Products Offered
Table 26. Drugs for Neuromyelitis Optica Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Drugs for Neuromyelitis Optica Consumption by Regions 2015-2020 (K Units)
Table 28. Global Drugs for Neuromyelitis Optica Consumption Market Share by Regions 2015-2020
Table 29. Global Drugs for Neuromyelitis Optica Value by Regions 2015-2020 ($ Millions)
Table 30. Global Drugs for Neuromyelitis Optica Value Market Share by Regions 2015-2020
Table 31. Americas Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020) (K Units)
Table 32. Americas Drugs for Neuromyelitis Optica Consumption Market Share by Countries (2015-2020)
Table 33. Americas Drugs for Neuromyelitis Optica Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Drugs for Neuromyelitis Optica Value Market Share by Countries (2015-2020)
Table 35. Americas Drugs for Neuromyelitis Optica Consumption by Type (2015-2020) (K Units)
Table 36. Americas Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
Table 37. Americas Drugs for Neuromyelitis Optica Consumption by Application (2015-2020) (K Units)
Table 38. Americas Drugs for Neuromyelitis Optica Consumption Market Share by Application (2015-2020)
Table 39. APAC Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020) (K Units)
Table 40. APAC Drugs for Neuromyelitis Optica Consumption Market Share by Countries (2015-2020)
Table 41. APAC Drugs for Neuromyelitis Optica Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Drugs for Neuromyelitis Optica Value Market Share by Regions (2015-2020)
Table 43. APAC Drugs for Neuromyelitis Optica Consumption by Type (2015-2020) (K Units)
Table 44. APAC Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
Table 45. APAC Drugs for Neuromyelitis Optica Consumption by Application (2015-2020) (K Units)
Table 46. APAC Drugs for Neuromyelitis Optica Consumption Market Share by Application (2015-2020)
Table 47. Europe Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020) (K Units)
Table 48. Europe Drugs for Neuromyelitis Optica Consumption Market Share by Countries (2015-2020)
Table 49. Europe Drugs for Neuromyelitis Optica Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Drugs for Neuromyelitis Optica Value Market Share by Countries (2015-2020)
Table 51. Europe Drugs for Neuromyelitis Optica Consumption by Type (2015-2020) (K Units)
Table 52. Europe Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
Table 53. Europe Drugs for Neuromyelitis Optica Consumption by Application (2015-2020) (K Units)
Table 54. Europe Drugs for Neuromyelitis Optica Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Drugs for Neuromyelitis Optica Consumption by Countries (2015-2020) (K Units)
Table 56. Middle East & Africa Drugs for Neuromyelitis Optica Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Drugs for Neuromyelitis Optica Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Drugs for Neuromyelitis Optica Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Drugs for Neuromyelitis Optica Consumption by Type (2015-2020) (K Units)
Table 60. Middle East & Africa Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Drugs for Neuromyelitis Optica Consumption by Application (2015-2020) (K Units)
Table 62. Middle East & Africa Drugs for Neuromyelitis Optica Consumption Market Share by Application (2015-2020)
Table 63. Drugs for Neuromyelitis Optica Distributors List
Table 64. Drugs for Neuromyelitis Optica Customer List
Table 65. Global Drugs for Neuromyelitis Optica Consumption Forecast by Countries (2021-2025) (K Units)
Table 66. Global Drugs for Neuromyelitis Optica Consumption Market Forecast by Regions
Table 67. Global Drugs for Neuromyelitis Optica Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Drugs for Neuromyelitis Optica Value Market Share Forecast by Regions
Table 69. Global Drugs for Neuromyelitis Optica Consumption Forecast by Type (2021-2025) (K Units)
Table 70. Global Drugs for Neuromyelitis Optica Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Drugs for Neuromyelitis Optica Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Drugs for Neuromyelitis Optica Value Market Share Forecast by Type (2021-2025)
Table 73. Global Drugs for Neuromyelitis Optica Consumption Forecast by Application (2021-2025) (K Units)
Table 74. Global Drugs for Neuromyelitis Optica Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Drugs for Neuromyelitis Optica Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Drugs for Neuromyelitis Optica Value Market Share Forecast by Application (2021-2025)
Table 77. Pfizer Product Offered
Table 78. Pfizer Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 79. Pfizer Main Business
Table 80. Pfizer Latest Developments
Table 81. Pfizer Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 82. CSL Product Offered
Table 83. CSL Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 84. CSL Main Business
Table 85. CSL Latest Developments
Table 86. CSL Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 87. Fresenius Product Offered
Table 88. Fresenius Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 89. Fresenius Main Business
Table 90. Fresenius Latest Developments
Table 91. Fresenius Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 92. Sandoz Product Offered
Table 93. Sandoz Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 94. Sandoz Main Business
Table 95. Sandoz Latest Developments
Table 96. Sandoz Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 97. Intas Product Offered
Table 98. Intas Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 99. Intas Main Business
Table 100. Intas Latest Developments
Table 101. Intas Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 102. Teva Product Offered
Table 103. Teva Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 104. Teva Main Business
Table 105. Teva Latest Developments
Table 106. Teva Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 107. Tianjin Kingyork Product Offered
Table 108. Tianjin Kingyork Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 109. Tianjin Kingyork Main Business
Table 110. Tianjin Kingyork Latest Developments
Table 111. Tianjin Kingyork Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 112. Gyjtrs Product Offered
Table 113. Gyjtrs Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 114. Gyjtrs Main Business
Table 115. Gyjtrs Latest Developments
Table 116. Gyjtrs Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 117. Baxter Product Offered
Table 118. Baxter Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 119. Baxter Main Business
Table 120. Baxter Latest Developments
Table 121. Baxter Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 122. NANG KUANG Product Offered
Table 123. NANG KUANG Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 124. NANG KUANG Main Business
Table 125. NANG KUANG Latest Developments
Table 126. NANG KUANG Basic Information, Company Total Revenue (in $ million), Drugs for Neuromyelitis Optica Manufacturing Base, Sales Area and Its Competitors
Table 127. Grifols Product Offered
Table 128. Grifols Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 129. Grifols Main Business
Table 130. Grifols Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 131. Grifols Latest Developments
Table 132. CBOP Product Offered
Table 133. CBOP Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 134. CBOP Main Business
Table 135. CBOP Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 136. CBOP Latest Developments
Table 137. Octapharma Product Offered
Table 138. Octapharma Drugs for Neuromyelitis Optica Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 139. Octapharma Main Business
Table 140. Octapharma Latest Developments
Table 141. Octapharma Basic Information, Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Drugs for Neuromyelitis Optica
Figure 2. Drugs for Neuromyelitis Optica Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Drugs for Neuromyelitis Optica Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Drugs for Neuromyelitis Optica Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Glucocorticoids
Figure 7. Product Picture of Immunotherapies
Figure 8. Product Picture of Other
Figure 9. Global Drugs for Neuromyelitis Optica Consumption Market Share by Type (2015-2020)
Figure 10. Global Drugs for Neuromyelitis Optica Value Market Share by Type (2015-2020)
Figure 11. Drugs for Neuromyelitis Optica Consumed in Acute Attack
Figure 12. Global Drugs for Neuromyelitis Optica Market: Acute Attack (2015-2020) (K Units)
Figure 13. Global Drugs for Neuromyelitis Optica Market: Acute Attack (2015-2020) ($ Millions)
Figure 14. Drugs for Neuromyelitis Optica Consumed in Remission Prophylactic Treatment
Figure 15. Global Drugs for Neuromyelitis Optica Market: Remission Prophylactic Treatment (2015-2020) (K Units)
Figure 16. Global Drugs for Neuromyelitis Optica Market: Remission Prophylactic Treatment (2015-2020) ($ Millions)
Figure 17. Global Drugs for Neuromyelitis Optica Consumption Market Share by Application (2015-2020)
Figure 18. Global Drugs for Neuromyelitis Optica Value Market Share by Application (2015-2020)
Figure 19. Global Drugs for Neuromyelitis Optica Sales Market Share by Company in 2017
Figure 20. Global Drugs for Neuromyelitis Optica Sales Market Share by Company in 2019
Figure 21. Global Drugs for Neuromyelitis Optica Revenue Market Share by Company in 2017
Figure 22. Global Drugs for Neuromyelitis Optica Revenue Market Share by Company in 2019
Figure 23. Global Drugs for Neuromyelitis Optica Sale Price by Company in 2019
Figure 24. Global Drugs for Neuromyelitis Optica Consumption Market Share by Regions 2015-2020
Figure 25. Global Drugs for Neuromyelitis Optica Value Market Share by Regions 2015-2020
Figure 26. Americas Drugs for Neuromyelitis Optica Consumption 2015-2020 (K Units)
Figure 27. Americas Drugs for Neuromyelitis Optica Value 2015-2020 ($ Millions)
Figure 28. APAC Drugs for Neuromyelitis Optica Consumption 2015-2020 (K Units)
Figure 29. APAC Drugs for Neuromyelitis Optica Value 2015-2020 ($ Millions)
Figure 30. Europe Drugs for Neuromyelitis Optica Consumption 2015-2020 (K Units)
Figure 31. Europe Drugs for Neuromyelitis Optica Value 2015-2020 ($ Millions)
Figure 32. Middle East & Africa Drugs for Neuromyelitis Optica Consumption 2015-2020 (K Units)
Figure 33. Middle East & Africa Drugs for Neuromyelitis Optica Value 2015-2020 ($ Millions)
Figure 34. Americas Drugs for Neuromyelitis Optica Consumption Market Share by Countries in 2019
Figure 35. Americas Drugs for Neuromyelitis Optica Value Market Share by Countries in 2019
Figure 36. Americas Drugs for Neuromyelitis Optica Consumption Market Share by Type in 2019
Figure 37. Americas Drugs for Neuromyelitis Optica Consumption Market Share by Application in 2019
Figure 38. United States Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 39. United States Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 40. Canada Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 41. Canada Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 42. Mexico Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 43. Mexico Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 44. APAC Drugs for Neuromyelitis Optica Consumption Market Share by Countries in 2019
Figure 45. APAC Drugs for Neuromyelitis Optica Value Market Share by Regions in 2019
Figure 46. APAC Drugs for Neuromyelitis Optica Consumption Market Share by Type in 2019
Figure 47. APAC Drugs for Neuromyelitis Optica Consumption Market Share by Application in 2019
Figure 48. China Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 49. China Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 50. Japan Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 51. Japan Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 52. Korea Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 53. Korea Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 54. Southeast Asia Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 55. Southeast Asia Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 56. India Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 57. India Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 58. Australia Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 59. Australia Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 60. Europe Drugs for Neuromyelitis Optica Consumption Market Share by Countries in 2019
Figure 61. Europe Drugs for Neuromyelitis Optica Value Market Share by Countries in 2019
Figure 62. Europe Drugs for Neuromyelitis Optica Consumption Market Share by Type in 2019
Figure 63. Europe Drugs for Neuromyelitis Optica Consumption Market Share by Application in 2019
Figure 64. Germany Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 65. Germany Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 66. France Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 67. France Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 68. UK Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 69. UK Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 70. Italy Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 71. Italy Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 72. Russia Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 73. Russia Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 74. Middle East & Africa Drugs for Neuromyelitis Optica Consumption Market Share by Countries in 2019
Figure 75. Middle East & Africa Drugs for Neuromyelitis Optica Value Market Share by Countries in 2019
Figure 76. Middle East & Africa Drugs for Neuromyelitis Optica Consumption Market Share by Type in 2019
Figure 77. Middle East & Africa Drugs for Neuromyelitis Optica Consumption Market Share by Application in 2019
Figure 78. Egypt Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 79. Egypt Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 80. South Africa Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 81. South Africa Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 82. Israel Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 83. Israel Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 84. Turkey Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 85. Turkey Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 86. GCC Countries Drugs for Neuromyelitis Optica Consumption Growth 2015-2020 (K Units)
Figure 87. GCC Countries Drugs for Neuromyelitis Optica Value Growth 2015-2020 ($ Millions)
Figure 88. Global Drugs for Neuromyelitis Optica Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 89. Global Drugs for Neuromyelitis Optica Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 90. Americas Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 91. Americas Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 92. APAC Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 93. APAC Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 94. Europe Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 95. Europe Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 96. Middle East & Africa Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 97. Middle East & Africa Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 98. United States Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 99. United States Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 100. Canada Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 101. Canada Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 102. Mexico Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 103. Mexico Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 104. Brazil Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 105. Brazil Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 106. China Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 107. China Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 108. Japan Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 109. Japan Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 110. Korea Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 111. Korea Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 112. Southeast Asia Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 113. Southeast Asia Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 114. India Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 115. India Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 116. Australia Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 117. Australia Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 118. Germany Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 119. Germany Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 120. France Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 121. France Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 122. UK Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 123. UK Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 124. Italy Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 125. Italy Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 126. Russia Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 127. Russia Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 128. Spain Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 129. Spain Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 130. Egypt Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 131. Egypt Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 132. South Africa Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 133. South Africa Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 134. Israel Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 135. Israel Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 136. Turkey Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 137. Turkey Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 138. GCC Countries Drugs for Neuromyelitis Optica Consumption 2021-2025 (K Units)
Figure 139. GCC Countries Drugs for Neuromyelitis Optica Value 2021-2025 ($ Millions)
Figure 140. Pfizer Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 141. CSL Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 142. Fresenius Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 143. Sandoz Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 144. Intas Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 145. Teva Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 146. Tianjin Kingyork Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 147. Gyjtrs Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 148. Baxter Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 149. NANG KUANG Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 150. Grifols Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 151. CBOP Drugs for Neuromyelitis Optica Market Share (2018-2020)
Figure 152. Octapharma Drugs for Neuromyelitis Optica Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets